HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Accepted manuscript (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Lim, C. T. Articles by Korbonits, M. PubMed PubMed Citation Articles by Lim, C. T. Articles by Korbonits, M.

C Lim, London, W2 2QG, United Kingdom
B Kola, Centre for Endocrinology, Barts and the London, London, United Kingdom
M Korbonits, Centre for Endocrinology, Barts and the London, London, United Kingdom

Correspondence: Chung Thong Lim, Email: chungthong{at}gmail.com

Abstract

AMP-activated protein kinase (AMPK) is a key molecular player in energy homeostasis both at cellular and whole body levels. AMPK has been shown to mediate the metabolic effects of hormones such as leptin, ghrelin, adiponectin, glucocorticoids and insulin as well as cannabinoids. Generally, activated AMPK stimulates catabolic pathways (glycolysis, fatty acid oxidation and mitochondrial biogenesis) and inhibits anabolic pathways (gluconeogenesis, glycogen, fatty acid and protein synthesis) and has a direct appetite-regulating effect in the hypothalamus. Drugs that activate AMPK, namely metformin and thiazolidinediones, are often used to treat metabolic disorders. Thus, AMPK is now recognised as a potential target for the treatment of obesity and associated co-morbidities.